Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
ArriVent’s phase 3 lung cancer trial flops, sinking stock
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57%.
Nick Paul Taylor
Oct 6, 2026 10:51am
Foghorn lays off 40% of employees as Lilly collab collapses
Oct 1, 2026 8:36am
BioNTech sets survival standard in hard-to-treat cancer
Sep 14, 2026 4:15am
GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset
Sep 3, 2026 7:45am
AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
Aug 17, 2026 4:45am
Taiho and Cullinan secure lung cancer victory to challenge J&J
Aug 13, 2026 6:00am
